Table 5 Sensitivity analysis of DEX, BORT and LEN/DEX: costs and cost-effectiveness ratios
Sensitivity | Treatment | Cost (R) | ICER (cost/QALY) |
|---|---|---|---|
Discount rate 0% | DEX | R 9001 | Â |
BORT | R 257 906 | 605 569 | |
LEN/DEX | R 1 312 357 | 1 147 418 | |
Discount rate 10% | DEX | R 7 741 | Â |
BORT | R 216 818 | 702 510 | |
LEN/DEX | R 1 003 823 | 1 299 670 | |
Outpatient costs − 50% | DEX | R 4 960 |  |
BORT | R 215 460 | 607 912 | |
LEN/DEX | R 1 130 014 | 1 244 907 | |
Outpatient costs + 50% | DEX | R 11 664 |  |
BORT | R 254 531 | 701 385 | |
LEN/DEX | R 1 140 632 | 1 206 177 | |
Inpatient costs − 50% | DEX | R 7 598 |  |
BORT | R 234 393 | 654 972 | |
LEN/DEX | R 1 134 750 | 1 225 582 | |
Inpatient costs + 50% | DEX | R 9 027 |  |
BORT | R 235Â 598 | 654 325 | |
LEN/DEX | R 1 135 897 | 1 225 502 | |
LEN drug price − 40% | DEX | R 8 312 |  |
BORT | R 234 996 | Dominated | |
LEN/DEX | R 386 478 | 349 861 | |
LEN drug price + 40% | DEX | R 8 312 |  |
BORT | R 234 996 | 654 649 | |
LEN/DEX | R 1 884 168 | 2 244 883 | |
BORT drug price − 40% | DEX | R 8 312 |  |
BORT | R 96 891 | 279 817 | |
LEN/DEX | R 1 030 119 | 1 402 216 | |
BORT drug price + 40% | DEX | R 8 312 |  |
BORT | R 589 737 | Dominated | |
LEN/DEX | R 1 135 323 | 742 662 |